

For a future beyond cancer

Impact Report 2015/16



Thank you for your support this year

The Royal Marsden was founded thanks to philanthropic support. It was a charitable gift that enabled Dr William Marsden to build the Free Cancer Hospital in 1851 – the first hospital in the world dedicated to treating and researching cancer. This tradition of philanthropy continues today with the wonderful supporters of The Royal Marsden Cancer Charity who help to ensure patients receive the very best cancer care not just at The Royal Marsden but across the UK and world-wide.

Over the last year we have supported many important projects across the hospital in the areas of cancer research, diagnosis, treatment and care. For example, it is thanks to our amazing supporters that we were able to fund The Ralph Lauren Centre for Breast Cancer Research, the development of new imaging techniques to enable more accurate diagnosis at The Reuben Foundation Imaging Centre, and groundbreaking research across all tumour types. We also launched the UK's first Robotic Surgery Fellowship and continued to provide services to support patients who are dealing with the effects of their current or former treatments.

But our work doesn't stop here. Over the next year and beyond, we will continue helping The Royal Marsden deliver its world-leading work to create a future beyond cancer for us all.

We would like to thank each and every one of our supporters, whether they have made a single donation, a regular monthly gift, run a marathon, or hosted a fundraising event. Your support is vital to helping patients at The Royal Marsden.



R. Ian Molson
Chairman
The Royal Marsden Cancer Charity



Cally Palmer CBE
Chief Executive
The Royal Marsden NHS Foundation Trust

Building a future beyond cancer

Your donations help to make our vision a reality; enabling us to fund the best equipment, facilities and projects so The Royal Marsden's expert teams can develop life-changing advances in cancer research, diagnosis, treatment and care for cancer patients nationally and internationally.

Research

Our clinical research teams are pioneering the development of many new treatments for different types of cancers, improving and saving more patients' lives.

Diagnosis

Our investment in equipment and facilities is delivering faster and more accurate diagnostic tests than ever before, resulting in personalised treatments for patients.

Treatment

Our funding of technology and equipment is allowing us to give patients access to the very best treatment options that are kinder and more effective.

Care

Our environments are peaceful and staff place the highest importance on patient dignity and care, so patients feel comfortable and reassured throughout their treatment.

Extraordinary things are happening

The Ralph Lauren Centre for Breast Cancer Research

Research We are committed to providing our researchers with the resources they need to run leading clinical trials.

In 2015, this included continuing work on the construction of The Ralph Lauren Centre for Breast Cancer Research. This world-class facility will be staffed by a team of leading clinicians and scientists working with the latest technology to set a benchmark for cancer research around the world.



The Breast Unit at The Royal Marsden is one of the largest in the UK with around 1,000 new breast cancer referrals every year. The new centre will increase the number and size of studies and trials the Breast Unit is able to run.

It will draw upon new technological advances to allow much more rapid and in depth analysis of patients' disease. The overall aim is to identify molecular differences between tumours that allow the optimal treatment of individual breast cancer patients.

“Our new centre and the programme running here will allow more rapid and in depth molecular analysis of our patients' disease. This could lead to more accurate diagnosis and treatment for patients.”

Professor Mitch Dowsett
Head of The Ralph Lauren Centre for Breast Cancer Research

The Reuben Foundation Imaging Centre

Diagnosis Patients at The Royal Marsden benefit from being diagnosed with the latest world-leading technology.

In 2014/15, the Reuben Family and other generous supporters helped to fund The Reuben Foundation Imaging Centre at our Chelsea hospital, which has now been in operation for a year. The centre is equipped with two state-of-the-art MRI scanners – 1.5T and 3T – as well as two CT scanners.

The new technology produces superior images which enable improved and earlier cancer detection and diagnosis. The scanners also have movement reduction technology to produce improved images of moving areas such as the heart and lungs.

The higher resolution images give our clinicians more information about a tumour – such as its metabolism – than ever before. Therefore, a more accurate diagnosis and targeted treatment decision can be reached, enhancing efficacy and reducing side effects.



The greater acuity of the images is also vital to our research. Patients at the point of diagnosis can now take part in clinical research studies at the centre, and in doing so are contributing to research that could help with their own cancer treatment and that of other patients in the future.

“Our research using the latest diagnostic equipment aims to benefit patients by improving treatment outcomes. By applying and developing new imaging techniques, we hope to discover which treatment is effective and whether patients are likely to benefit from a particular treatment.”

Dr Kate Newbold
Consultant Clinical Oncologist

every day at The Royal Marsden

The da Vinci Xi Robotic Surgery Fellowship

Treatment We're training consultants in robotic surgery techniques so more people can rapidly recover from surgery.

Robotic surgery is the manipulation of robotic arms that operate through tiny incisions in the body. It is exceptionally precise and therefore reduces trauma to the body, meaning a patient can recover much faster.



Thanks to a generous donation from the McCarthy family, last year we purchased a new surgical robot – the da Vinci Xi. It has a magnified 3D view that allows surgeons to conduct precise, minimally invasive operations without the need for more risky open surgery.

One of the da Vinci Xi's most innovative functions is to facilitate the training of surgeons in robotic surgery techniques, in such a way as to provide the best possible hands on experience whilst maximising patient safety.

This year our supporters raised sufficient funds to enable the launch of our Robotic Surgery Fellowship. This programme will facilitate the training of up to ten additional surgeons in robotic surgery techniques over the next ten years. The Fellowship will rotate between three specialities: urology, gynaecology and colorectal so they can operate on tumours anywhere in the pelvic and abdominal region.

“By growing our team of robotic surgeons through the Fellowship, we will be able to offer world-leading surgery to even more patients both at The Royal Marsden and across the country.”

Mr Pardeep Kumar
Consultant Urological Surgeon and Robotic Surgery Lead for The Royal Marsden

Providing patients with the best possible support

Care Thanks to our supporters we fund projects that help our patients cope with their treatment.

In December 2014, we launched an appeal to raise £4.5m to fund a range of services that improve our patients' experiences. For example, our supporters are now funding psychological support and pastoral care for patients dealing with the effects of their diagnosis and treatment, and training for staff about the psychological needs of patients. Over the last year, the adult psychological support team received over 750 new outpatient referrals and provided over 3,000 individual therapeutic sessions.



We are also raising funds towards the Family Support Service which specifically supports cancer patients who are parents of children under 18 years. This is the only service of its kind in the UK and relies entirely on charitable support

“My goal is to ensure that a family is able to communicate and effectively support each other, so that they can cope with a very difficult situation together.”

Dr Lucy Grant
Clinical Psychologist

The da Vinci Xi – Timothy’s Story

Timothy Mitchell, 29, was diagnosed with testicular cancer in January 2016 and had his right testicle removed, before being transferred to The Royal Marsden for surveillance and follow up scans. Not long after, one of the scans picked up an enlarged lymph gland which was a sign that the cancer had spread.

“I met the surgical team and they offered me a robotic-assisted abdominal lymph node removal.

Only around 20 patients over the last few months have had this procedure with the da Vinci Xi surgical robot so there is no long term data, but the surgeons thought it was a good option for me and it seemed like the best choice.

The procedure went really well and the affected nodes were removed. I recovered incredibly quickly and was up and walking around the next day – if I had had open surgery it would have taken weeks, if not months, to fully recover.

I’m at less risk of infection and now have five small incisions that will heal nicely over time instead of a large scar across my abdomen.



I was told I would be able to return to work within a couple of weeks rather than 12 and I don’t need to be on strong painkillers, which can sometimes affect your mental health.

I’m amazed that I’ve recovered so well and it’s given me a lot more confidence in the future – I’m so thankful that I was able to have this type of surgery. It means I won’t have to undergo intensive radiotherapy or chemotherapy treatment, which can have very negative effects on your body.”

Looking forward to 2016/17 and beyond

With more people being diagnosed with cancer than ever before, The Royal Marsden needs to continue to innovate and develop to give more patients access to world leading care and research, so that we can save more lives.

Next year, we aim to support many new and exciting projects that will further strengthen The Royal Marsden’s pioneering clinical research, create new facilities equipped with the very best technology, and provide first-class care to all patients. With your help, we will be able to ensure that the hospital can continue to improve the lives of cancer patients everywhere.

Supporting research and innovation in radiotherapy

We are aiming to install a new True Beam™ linear accelerator by February 2017, to enable patients to be treated with the most up-to-date radiotherapy equipment. The technology will improve patient experience and ensure greater access for patients to stereotactic radiotherapy, as well as being used in pioneering research trials of advanced radiotherapy techniques.

Supporting young patients through play therapy

Every child that walks through the doors of our Oak Centre for Children and Young People for treatment meets a play specialist. They help our young patients through their fears by building relationships and putting strategies in place to help them cope. Next year we will fund this vital service supporting young cancer patients through diagnosis and treatment.

Pioneering clinical care and research

We are committed to building The Clinical Care and Research Centre at The Royal Marsden, Sutton, enabling us to speed up progress by bringing researchers, clinicians and patients together under one roof. Opening in 2021, the centre will make sure as many patients take part in trials as possible, help to speed up the introduction of new treatments and enable us to see thousands more patients each year.

How much we raised

Total income

Voluntary income	£14.6m
Investment income	£1.3m
Other	£0.2m
Total	£16.1m

Voluntary income

Together, we raised over £14.6 million in 2015/16. This amount is testament to the incredible generosity and hard work of our dedicated supporters over the past year.

We are enormously grateful to everyone who helped provide us with the money we need to fund pioneering work in cancer research, diagnosis, treatment and care at The Royal Marsden.

Over 80p
of every
£1 donated




was available to spend on the latest developments in cancer research, diagnosis, treatment and care.

Legacy income

Legacy income accounted for 27% of our voluntary income in 2015/16, with £3.9 million left to us in people's wills. It's a source of income that's exceptionally important to the planning and funding of life-changing projects at The Royal Marsden. We are incredibly grateful to everyone who has generously given us a legacy gift.


Investment income

We have a portfolio of investments that are managed by professional investment managers, according to guidelines and responsible policies agreed with our Trustees. These support existing grant commitments and provide working capital for planned major future commitments and running expenses. This helps to make sure the greatest possible percentage of our voluntary income directly improves the lives of patients at The Royal Marsden and people with cancer in the rest of the UK and around the world.



- A. Individuals and trusts £5.6m**
- B. Legacies £3.9m**
- C. Community and corporate £4.9m**
- D. Trading £0.2m**

How we spent your money



Total expenditure

- A. Charitable support of the hospital £14.8m**
- B. Raising funds £2.8m**
- C. Investment and property management £0.3m**
- Total £17.9m**

Charitable support of the hospital

Thanks to our supporters' generosity, we invested over £14 million last year to fund groundbreaking clinical trials, new patient facilities, state-of-the-art equipment and patient services at The Royal Marsden. This investment is vital to provide patients with the very best in cancer research, diagnosis, treatment and care.

Raising funds

These are the direct costs that the Charity incurs to raise its voluntary income. Last year, this investment was 19.2% of the voluntary income raised.

Investment and property management

These costs include fees paid to investment and property managers and associated direct costs.

Future commitments and resources

The pace at which cancer research is progressing, and the new opportunities this offers to improve and save lives, means it is vital that we provide The Royal Marsden with greater funding.

As of 31 March 2016, we had outstanding grants totalling £17.4 million to spend over the next three years. This includes the remainder of the £9 million investment into a programme of clinical and translational research, the £4.5 million grant for improving the quality of patient services at The Royal Marsden, the £4 million grant for building workforce excellence at The Royal Marsden, the grants for The Clinical Care and Research Centre and the True Beam™ linear accelerator.

Based on priority need plans discussed with The Royal Marsden, in March 2016 Trustees set aside £18.5m of reserves designated for grants we expect to make in 2016/17. These include the renewals of the grants for the programme of clinical and translational research, and drug development (£10.5 million) and improving the quality of patient services at The Royal Marsden (£4.5 million), and new grants for equipment for improving diagnosis, treatment and care (£3.5 million). We expect to receive a number of further new applications to fund significant projects prioritised by The Royal Marsden. This is why every penny you donate or fundraise for the Charity is so important.

For more information about our finances, including our full annual report and financial statements, please visit our website or our page on the Charity Commission's website.

Trustees

R. Ian Molson
Chairman,
The Royal Marsden
NHS Foundation Trust
Ex-officio Trustee

Richard Turnor
Non-Executive Director,
The Royal Marsden
NHS Foundation Trust
Appointed Trustee

Cally Palmer CBE
Chief Executive,
The Royal Marsden
NHS Foundation Trust
Ex-officio Trustee

Robin Broadhurst CBE
Elected Trustee

Richard Oldfield
Elected Trustee

Professor Martin Gore CBE
Consultant
Medical Oncologist
(Medical Director
to January 2016),
The Royal Marsden
NHS Foundation Trust
Appointed Trustee

Emmanuel Roman
Elected Trustee

Sir John Rose
Elected Trustee

Lady Helen Taylor
Elected Trustee

Our Board of Trustees have a wide range of expertise. Advised by the hospital but not governed by it, it approves strategic priorities that are aligned with those of the hospital, and considers and takes all other strategic decisions.

Thank you

We would like to say a huge thank you to everyone who has helped us over the last year, in particular the following supporters:

Philanthropist

The David Adams
Leukaemia Appeal Fund
Catherine & John Armitage
The City Challenge Golfers
The Bud Flanagan
Leukaemia Fund
Friends of The Royal Marsden
The Raz Gold Foundation
Ralph Lauren
The Marsden Marchers
Don McCarthy & Children
Oak Foundation
The Presidents Club
Charitable Trust
The Reuben Foundation
Jimmy Thomas
The Garfield Weston
Foundation
The Charles Wolfson
Charitable Trust
The Wolfson Foundation

Benefactor

The Arbib Foundation
The Arthur Foundation
Eric & Chrysta Baldwin
The Banham Foundation
Bank of Scotland Corporate
The Breast Cancer
Research Foundation
The Butchers Arms
Restaurant
The Derek Butler Trust
Ning Ning Chang Craven
Elayne & Richard Cyzer
Philip Gould Tribute Fund
Gynaecological Cancer Fund
The Helen Hamlyn Trust
The Paul Hamlyn Foundation
House of Fraser
Sam Keen Foundation
The Kay Kendall
Leukaemia Fund
The Jimmy Knapp
Cancer Fund
Le Cure de France

The Luck-Hille Foundation
T & J Meyer Family
Foundation
Martin Myers
Richard Oldfield
The P F Charitable Trust
Richard & Victoria Sharp

Affiliate

Bookham Amateur
Golf Society
The G & K Boyes
Charitable Trust
The Dr Lucy M Bull
Lectureship and
Research Fund
The Cadogan Charity
Carshalton Pantomime
Company
Katie Compson Foundation
Ramzi Dalloul
The Ellison Family
Robert Hogan
Harry Hyman
Katie's Lymphoedema Fund
Kensington Mayor's Fund
The Moodie Report
Foundation
Phoenix Martial Arts
Rally for Kids
The Revere Charitable Trust
The Stanley Sanger
Foundation
The Sohn Conference
Foundation
The Peter Stebbings
Memorial Trust
The Caroline Menez Trust
and The Wellesley
Wimbledon Village Stables

Associate

The Michelle Adams Fund
AEG
Peter J Allen
Atlantic Trading LLP
B.E.L.L.E.
Anni Bain

Beaufort Polo Club
Berwin Leighton Paisner LLP
The Book People
Victoria Brahm Schild
Brakes
Luigi Carnevale
The Josh Carrick Foundation
The John Coates
Charitable Trust
Julian P Colborne-Baber
The Conde Nast
Publications Ltd
Marcus Cooper
Emperor Designs
The Eranda Foundation
The Fairstead Trust
Father & Son Day
The Alison Fracella
Research Trust
Derrick & Beryl Frost
The Robert Gavron
Charitable Trust
Goldsmiths
Jennifer Greene
Halcyon Gallery
Hamsey Furniture Co. Limited
Michael Hounsom
Team Harry
Incentive FM Group Ltd
Stewart Jackson
The Dorothy Jacobs Charity
Robert Johns
Leukaemia Fund
David Juda
Philip Kingsley
Legal & General
Ross & Deborah Luke
Mayer Brown
International LLP
Melanoma UK
Middlesex Masonic Charity
Natta Building Company
Salomon Oppenheimer
Philanthropic Foundation
Parkside School

The Pears Family
Charitable Foundation
Pearson Cycle Specialists Ltd
Mr & Mrs Perren
Richard Phillips
Reed Business Information
The Harriet Roberts
Foundation
Emmanuel & Barrie Roman
Jim Rymer
Rosie Savory
Lenya Savvides
Seaton House School
Geoffrey Selby
Virginia A Slaymaker
Stonehage Fleming
Family and Partners
Alistair Subba Row
Darren Swain
Maria Thurston-Ryan
Just Beat It
The Myfanwy Townsend
Melanoma Research Fund
Surrey Spring Show
Committee
Charlie Young & Family

Platinum

Navchetna BV
Charitable Trust
Central Ward Residents
and Sports Club
The Bernard Coleman Trust
The John Cowan Foundation
Norma Darter
Dominic & Claire Freemantle
The Harrison-Frank
Family Foundation
Gerald Hawkins
The Golden Bottle Trust
John Q. H. Hippisley
H M Horton
Patrick Morrissey
Dusty Springfield
Judette & Gavin Sanderson
ShareGift

Charity Registered Office

The Royal Marsden, Fulham Road, London, SW3 6JJ
T 020 7808 2233 E philanthropy@royalmarsden.org
www.royalmarsden.org

The
**CHARITIES
FORUM**

Founded by
The Duke and Duchess of Cambridge
and Prince Harry



The Royal Marsden Cancer Charity
Registered Charity No. 1095197. A charitable
company limited by guarantee registered in
England No. 4615761